Intention-to-treat analyses and missing data approaches in pharmacotherapy trials for alcohol use disorders

BMJ Open

Volumn 3, Issue 11, 2013, Pages

  Del Re, A C ^a   Maisel, Natalya C ^a   Blodgett, Janet C ^a   Finney, John W ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL USE DISORDER; ARTICLE; DATA ANALYSIS; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; PHARMACEUTICAL CARE; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; SURVIVAL;

EID: 84888097288     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003464     Document Type: Article

References (13)

1. Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res 2011;2:109-12.
2. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670-4. (Pubitemid 29423954)
3. Little RJ, Rubin DB. Statistical analysis with missing data. Wiley New York, 1987.
4. Ruiz-Canela M, Martínez-González MA, De Irala-Estévez J. Intention to treat analysis is related to methodological quality. BMJ 2000;320:1007.
5. Moher D, Schulz K, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol 2001;1:2.
6. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg. Published Online First: 2011. http://www.sciencedirect.com/science/article/pii/S1743919111005620 (accessed 6 Mar. 2013).
7. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. Published Online First: 2008. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266844/ (accessed 6 Mar. 2013).
8. Polit DF, Gillespie BM. Intention-to-treat in randomized controlled trials: recommendations for a total trial strategy. Res Nurs Health 2010;33:355-68.
9. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 2002;359:781-5. (Pubitemid 34215082)
10. Avins AL, Pressman A, Ackerson L, et al. Placebo adherence and its association with morbidity and mortality in the studies of left ventricular dysfunction. J Gen Intern Med 2010;25:1275-81.
11. Granger AL, Fehnel SE, Hogue SL, et al. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord 2006;90:217-21. (Pubitemid 43183531)
12. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol 2009;62:499-505.
13. Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013;108:275-93.